Introduction
The emergence of COPD phenotypes Chronic obstructive pulmonary disease (COPD) is a significant public health concern that has worldwide repercussions as an important source of mortality and morbidity [1] [2] [3] . Although scientific progress regarding COPD may have been hindered by its perception as a self-inflicted and irreversible disease [4] , the last decades have witnessed an increasing interest in research regarding the epidemiological and pathophysiological aspects of COPD, as well as the development of new therapeutic agents. Since the first Global Initiative for Obstructive Lung Disease (GOLD) statement was published in 2001, there has been growing understanding of the clinical relevance of the heterogeneous and complex nature of the disease. Although the last update of the GOLD statement still suggests a definition of COPD based on lung function indices, it also clearly acknowledges the importance of other disease components, such as dyspnoea, exacerbations and disability/health status [5] . This allows clinicians to modulate their assessment of the disease's severity beyond the classical FEV 1 criterion, which alone is known to be an imperfect reflection of disease burden [6] and prognosis [7, 8] . Chronic activityrelated dyspnea, for example, is recognised as a better predictor of mortality [9] than FEV 1 alone.
The recognition that COPD is a multifaceted entity is far from novel [10] [11] [12] , but it is only recently that its different clinical presentations were identified and integrated as relevant potential markers of symptomatology, response to treatment and prognosis: the so-called COPD phenotypes [13] [14] [15] [16] [17] [18] .
A group of expert defined these COPD phenotypes as "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes (symptoms, exacerbations, response to therapy, rate of disease progression, or death)" [19] . Many such phenotypes have been tentatively described: emphysema-hyperinflation, chronic bronchitis, and asthma-COPD overlap syndrome, the first two being further possibly associated with the frequent or infrequent exacerbator profile [13, 17, 20] . Of note, the term "phenotype" usually refers to the actual observable characteristics and properties of an organism, which stem from the interaction between its genetic background and its environment. Although considerable progress has been made regarding the genetic determinants of COPD since the sequencing of the human genome, there is still insufficient data to clearly delineate a unique causative genetic component for each of these proposed subgroups. It is therefore important to emphasize the clinical nature of these phenotypes.
This review will focus on the emphysema-hyperinflation (EH) phenotype. Although no clear and generalized definition of this phenotype has been described, we will, for the purpose of this review, define it as a subgroup of patients that present with predominant dyspnea, a significant emphysema burden (assessed using either computed tomography scanner or pulmonary function testing) and/or lung hyperinflation (assessed using pulmonary function testing), while not presenting characteristics associated with other recognized phenotypes such as chronic bronchitis or asthma-COPD overlap syndrome.
Review

Identification of the emphysema-hyperinflation phenotype Genetic determinants
The observations that only a minority of smokers will develop COPD and that there are instances of familial clustering of COPD among relatives of patients with the disease support the fact that genetic factors play a role in the pathogenesis of COPD. A complete overview of the potential genetic determinants of COPD is beyond the scope of this text, but we briefly review some of the evidence regarding emphysema and hyperinflation.
Single nucleotide polymorphisms (SNPs) linked to the development of emphysema have been identified in several candidate genes in recent years, especially following the National Emphysema Treatment Trial (NETT) [21] . These SNPs usually involve genes related to xenobiotic metabolism, preservation of the extracellular matrix, host defense, control of inflammation and telomere regulation. Polymorphisms in glutathione S-transferase P1 (GSTP1) and microsomal epoxide hydrolase (EPHX1) are associated with apical emphysema and rapid lung function decline [22] [23] [24] [25] . SNPs in EPHX1 are also related to exercise capacity, D L CO and dyspnoea [26] .
Recently, the first genome-wide association study of hyperinflation was performed in patients of the COPD-Gene [27] , Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) [28] and GenKOLS [29] studies. A SNP in dynein, axonemal, heavy chain 5 (DNAH5) was associated with increased computed tomography (CT) derived total lung capacity (TLC). DNAH5 encodes a dynein found in the respiratory cilia and whose mutation can cause primary ciliary dyskinesia type 3 or Kartagener syndrome. In this study, no data relative to exercise tolerance, symptoms or other markers of hyperinflation were available [30] .
Characteristics of the EH phenotype: Hyperinflation
Static hyperinflation Central to the concept of the EH phenotype is static hyperinflation, which refers to the reset of the resting relaxation volume of the respiratory system to an abnormally high volume, and mainly results from changes in the elastic proprieties of the lung and chest wall [31, 32] . It is important to recognise that the term "static" refers to the determination of lung volumes using the static pressure-volume relaxation curve of the respiratory system [33, 34] (see Fig. 1 ).
While the criteria used to diagnose airway obstruction (using FEV1/FVC ratio) and assess its severity (using FEV1) are uniformly recognized [5, 35] , the presence and severity of gas trapping and static hyperinflation can be described using a plurality of indices, the most common being residual volume (RV), functional residual capacity (FRC), total lung capacity (TLC), RV/TLC ratio and FRC/ TLC ratio. Although no precise cut-off value for these indices has been defined, it is generally accepted that lung hyperinflation is present when they exceed either the upper limit of normality (ULN, as defined as the upper 95 % confidence limit of a reference population) or an arbitrary 120 % of the predicted value. Thus, an elevated value of RV and/or RV/TLC implies pulmonary gas trapping, while an abnormally high FRC, TLC and/or FRC/ TLC ratio signify lung hyperinflation. Of note, while the use of resting inspiratory capacity (IC) or IC/TLC ratio to assess hyperinflation is frequent, it must be emphasized that in some patients with significant lung hyperinflation, end-expiratory lung volume (EELV) and TLC may increase in a parallel and proportional way, leading to a preserved IC. In the same manner, if hyperinflation is concomitant to other conditions influencing EELV (such as respiratory muscle weakness) or TLC (such as interstitial lung disease), IC becomes an unreliable marker of hyperinflation.
Recent data suggest that among these indices, a larger FRC, TLC and decreased IC/TLC are preferentially associated with percent emphysema on CT scan, greater dyspnoea and lower body mass index (BMI)all characteristics of the EH phenotype [36] .
The natural evolution of hyperinflation in patients with COPD is unclear, but data suggest that it can present even in patients with mild COPD, and increases exponentially as disease severity worsens [37] . On a related note, there is increasing evidence supporting the correlation of CT-derived emphysema assessment with physiological markers of hyperinflation (most commonly RV, RV/TLC and resting IC and FRC) [38] [39] [40] [41] [42] .
Of interest is the observation that significant lung hyperinflation may alter the measurement of forced expiratory flows. During a forced expiratory manoeuvre, thoracic gas is compressed by the increase in intrathoracic pressures, causing a decrease in lung volume and elastic recoil that will in turn decrease driving airflow pressure and FEV1 [43] . Measurement of compressionfree FEV1 using body plethysmography confirms that it is underestimated in patients with significant hyperinflation, to the extent of affecting the grading of disease severity [44] . This finding supports the increasingly prevalent notion that FEV 1 alone can be misleading or unreliable when trying to grade COPD severity.
Dynamic hyperinflation
In contrast to static hyperinflation (which, as mentioned, refers to an increase of FRC above the 95th percentile of the predicted value when the elastic recoil pressure of the respiratory system is zero [33] ), dynamic hyperinflation (DH) refers to an "increase of the FRC above the relaxation volume in situations where the duration of expiration is insufficient for deflating the lung to its relaxation volume prior to the next inspiratory effort and where, as a result, the elastic recoil pressure of the respiratory system becomes positive". [33, 45, 46] . As a result, operating lung volumes progressively shift closer to TLC, tidal volume expansion becomes limited by high intrathoracic pressures and work of breathing is increased [47] (see Fig. 2 ). The discrepancy between tidal volume expansion limitation and increasing neural respiratory drive (neuromechanical uncoupling) sharply EELV is set at the point at which the elastic recoil pressures of the lung and chest wall are equal and opposite in direction. In COPD patients with hyperinflation, emphysema decreases lung elastic recoil pressure and causes a reset of functional residual capacity, or EELV, at a higher absolute lung volume. The difference between expected (long-dashed lines) and observed EELV (short-dashed lines) represent static hyperinflation increases shortness of breath [48] [49] [50] , and a mechanical dyspnoea threshold is reached when inspiratory reserve volume (IRV) decreases to approximately 0.6-0.4 L [51] . Further increase in minute ventilation will preferentially be accomplished by increased respiratory rate, with consequently deceased expiratory time, which aggravates DH to a greater extent.
The presence of DH is correlated to resting hyperinflation [45, 52] , disease severity [48] , exercise tolerance, dyspnoea and mortality, [45, 48, 53, 54] and as such is a hallmark of the EH phenotype.
However, the direct role of DH as a limiting factor during exercise in COPD has been challenged by a study that found no difference in exercise capacity or dyspnoea rating during constant work-rate cycle exercise in hyperinflated COPD patients at rest presenting with and without DH [55] . In this study, although both groups of patients showed significant resting hyperinflation, patients who did not hyperinflate during exercise had a slightly higher FEV1/FVC ratio and less resting lung hyperinflation (FRC%pred and TLC%pred were less than the hyperinflators group), suggesting less airway dysfunction than the group who hyperinflated. Given that ventilatory demand and the volume and timing components of breathing during exercise were similar in both groups, we can assume that differences in IC behaviour during exercise primarily reflected unmeasured differences in mechanical time constants for lung emptying. Nonetheless, the attainment of a critical mechanical tidal volume/IRV constraint on exertion (which was similar in both groups) appeared to be a more pivotal contributor to exercise-induced dyspnoea than absolute DH.
Characteristics of the EH phenotype: Emphysema
Emphysema is pathologically defined as lung tissue destruction and dilatation beyond the terminal bronchioles [56] . The EH phenotype, when contrasted with chronic bronchitis, is characterised by a larger emphysema burden, and DLCO can be used to approximate pathological and radiological emphysema [41, [57] [58] [59] [60] . FEV1 in itself is more poorly related to radiological emphysema in some [40, 61, 62] , but not all [39, 41, 42, 63] studies. These findings suggest that CT scanning may play a role in the punctual or longitudinal assessment of the severity of COPD, especially when emphysema is the predominant pattern [64] .
Clinical relevance of the emphysema-hyperinflation phenotype Respiratory symptoms and exercise tolerance
Hyperinflation and emphysema are related to respiratory symptoms and quality of life [45, 62] . Compared with patients with COPD and normal lung volumes, those with resting hyperinflation have higher baseline dyspnoea [36, 65, 66] and significant intolerance to exercise [45] . Albuquerque et al. studied a cohort of patients with COPD and described how resting IC/TLC was the best predictor of a low peak oxygen uptake (VO2) during incremental cardiopulmonary testing, with a cut-off value of 0.28 having a sensitivity and specificity of 80.0 % and 89.6 % in identifying patients with a peakVO2 of less than 60 % predicted [67] . Similarly, Diaz et al. showed that, in a similar cohort, IC was strongly correlated to peakVO2 and that, in patients with resting expiratory flow limitation, it was the sole predictor of aerobic capacity [53] . O'Donnell et al. reported that, in 105 patients with COPD undergoing incremental exercise testing, peakVO2 correlated best with peak tidal volume reached, which itself was closely related to DH. Moreover, when compared with COPD patients with a preserved DLCO, patients with a reduced DLCO (and, presumably, a larger emphysema burden compatible with the EH phenotype) had lower peak VO2, larger resting hyperinflation and more frequently had dyspnoea as exercise stopping reason, despite no difference in FEV1 between the groups [45] . The almost universal exercise intolerance of patients with EH phenotype has repercussions in their everyday lives, and hyperinflation again emerges as an important predictive factor in this context. A study of 56 COPD evaluated the relation between lung function indices (including a measure of DH during an activity of daily living (ADL) task performed at the patient's home) and average daily physical activity. The authors found that both resting IC/TLC ratio and ADL-induced change in IC were the two main determinants of daily activity levels, with no significant contribution of FEV1 [68] .
Garcia-Rio et al. similarly reported that, in patients with COPD, the presence of DH, the absolute change in IC during exercise and the 6-minute walking distance explained 89 % of the variance in mean daily physical activity [69] , while FEV1 correlated with activity only in univariate analyses. Finally, in a study evaluating the magnitude of DH during self-paced ADL across COPD severity groups, Hannink et al. showed that DH occurs irrespective of disease severity, but that there was a trend for a lesser magnitude of change in EELV in the most severe patients. This could either be explained by the fact that GOLD IV patients have more resting hyperinflation and cannot generate as much "new" hyperinflation as the others, or by the fact that these patients seemed to have performed ADL with lesser metabolic cost (lower VO2 and minute-ventilation). Although the study was not specifically designed to assess this, IRV during ADL was correlated to FEV1 and decreased to 0.51 liters in GOLD IV patients, who also described a significantly higher level of dyspnoea [52] . This seems consistent with the notion that a critical mechanical constraint of IRV, rather than absolute DH, relates to exercise-induced dyspnoea.
Body mass index, muscle wasting and osteoporosis
Echoing Frank Netter's classic representation of the cachectic pink puffer patient, some studies have reported a relationship between the EH phenotype and a low BMI and/or peripheral muscle strength [36, 62, 65, 70, 71] . The pathophysiology behind the changes in body composition seen in some patients with COPD remains unclear, but evidence suggests it may be related to an increased secretion of inflammatory cytokines [72] [73] [74] [75] [76] [77] . Resistive breathing, which mimics the increased work of breathing experienced by patients with hyperinflation, has been shown to directly induce a systemic inflammatory response [78] .
In addition, serum and bronchoalveolar lavage levels of adiponectin are higher in patients with COPD than in healthy subjects [79] , and adiponectin-deficient mice seem protected against the development of emphysema and inflammation in response to cigarette smoke [80] . In humans, CT-assessed emphysema and low BMI are closely related to serum adiponectin levels [81] . Although it is still unclear whether adiponectin has a causative role in the pathophysiology of emphysema or is secreted in reaction to increased systemic inflammation, this cytokine shows promise as a potential marker of COPD, and of the EH phenotype. Finally, there is increasing data supporting the association of COPD and osteoporosis. The causative mechanisms underlying this association are still being investigated, but are likely modulated by gender, clinical phenotype (with a significant relationship to the severity of emphysema) and genetic predisposition [82] [83] [84] [85] .
Cardiovascular disease
Both hyperinflation (by increasing intrathoracic pressures) and emphysema (by destroying distal pulmonary vessels) have negative consequences on cardiac and circulatory function by decreasing ventricular preload, size and function. Barr et al. showed that, in a population-derived sample, CT emphysema and FEV1/FVC ratio were significantly correlated to left ventricular end-diastolic volume, stroke volume, cardiac output, but not to left ventricular ejection fraction [86] . Similarly, Jorgensen et al. compared patients with significant baseline hyperinflation (mean RV 272 % predicted and mean FRC 219 % predicted) to matched controls and found lower intrathoracic blood volume, left and right diastolic ventricular volume indexes, cardiac index and stroke volume index in patients with hyperinflation [87] . In this study, the correlation between intrathoracic blood volume and left ventricular end diastolic volume index highlights the role of decreased ventricular preload in the lower cardiac function in hyperinflated patients.
Vassaux et al. showed that severe resting hyperinflation (IC/TLC < 0.25) was associated with decreased exercise capacity and a lower peak oxygen pulse, and that IC/TLC was strongly correlated (r = 0.95) to peak oxygen pulse across disease severity, both in COPD patients and in controls [88] . Watz et al. similarly showed that static hyperinflation (evaluated using IC/TLC, FRC and RV) correlated better with the size of the cardiac chambers than the degree of airflow obstruction or DLCO [89] . Left ventricular diastolic dysfunction [90] and left atrial size [91] were also reported as being altered in patients with hyperinflation.
Whether the cardiopulmonary effects of hyperinflation are related to clinical outcome in patients with the EH phenotype in unclear, but there is evidence supporting the fact that the decrease in hyperinflation induced by bronchodilator therapy can improve right ventricular function [92] . In addition, as several large trials have reported trends for a decrease in mortality with the use of bronchodilators and lung volume reduction surgery (LVRS) in COPD, it is possible that part of this effect was related to a bronchodilator-or surgery-induced decrease in hyperinflation and consequent unloading of the cardiocirculatory system [13, [93] [94] [95] [96] [97] . In addition, the decrease in hyperinflation induced by bronchodilator therapy has been shown to improve right ventricular function
Prognosis
In a large multicenter cohort of patients with COPD (n = 689) followed for a mean of 34 months, an IC/ TLC ratio < 0.25 was a significant and independent predictor of mortality, and globally performed better than FEV1 alone, although not better than the BODE index [98] . Although this study underscored the importance of the IC/TLC ratio as a prognostic marker in a general COPD population, the precise proportion of "EH" or other phenotypes in this COPD cohort was not reported.
In the medical treatment arm of the NETT study [21] , high-risk patients (defined as FEV1 < 20 % predicted and either DLCO < 20 % predicted or homogenous emphysema of CT) had a higher mortality rate. In a multivariate mortality model, RV was among the independent predictors of mortality in this cohort, as were the presence of a low BMI, DLCO, and others. In this subgroup of patients with very severe disease, IC/TLC was only associated with mortality in univariate analyses [99] .
Other characteristics of the EH phenotype have been shown to be independent predictors of mortality, such as CT-assessed emphysema [100] , a higher dyspnoea level [9] , low BMI [100] [101] [102] and exercise (in)tolerance [99, 103, 104] .
Concerning disease evolution, emphysema [105] and CT-derived hyperinflation [106, 107] have been shown to be related to a faster FEV1 decline and to an increased exacerbation frequency in some [108] , but not all studies [109] .
Treatment
Smoking cessation remains the first and foremost therapeutic intervention in patients with COPD, and can significantly reduce disease progression [110] [111] [112] .
As reviewed, hyperinflation is closely related to dyspnoea and exercise capacity, and as such is an attractive treatment target in patients with EH phenotype. In recent years, many pharmacological studies have included the evaluation of clinically relevant outcomes other than FEV 1 such as hyperinflation and/or exercise capacity. However, it is important to note that most pharmacological-related studies have been conducted in COPD patients with no specification of their underlying phenotype.
Bronchodilators, both short-and long-acting betaagonists and anticholinergics, significantly decrease static and dynamic hyperinflation, improve IC during exercise (delaying the reaching of a critical IRV), improve dyspnoea and increase forced expiratory flows and exercise capacity. Some also have a positive effect on exacerbation rates, healthcare utilisation and, possibly, mortality [93, 94, 96, [113] [114] [115] [116] [117] [118] . One study highlighted the fact that bronchodilators predominantly exert their effects on measures of resting hyperinflation, even when little or no change in FEV1 is observed [37] . In addition, a study investigating the predictors of improvement in exercise tolerance following treatment of short-acting bronchodilator (ipratropium bromide, three times a day for a 3-week period) found that an increased resting IC was the best predictor of change in endurance time following bronchodilation, and that the change in FEV1 was not [119] .
Long-acting beta-agonists such as salmeterol and formoterol have been shown to decrease resting and dynamic hyperinflation and increase exercise performance [120] [121] [122] [123] [124] , although this improvement did not always reach clinical significance. Indacaterol, tiotropium, glycopyrronium bromide and aclidinium bromide also showed their ability to positively impact hyperinflation and improve exercise capacity [92, [125] [126] [127] [128] [129] [130] [131] [132] [133] .
The use of a combination of long-acting bronchodilators is suggested in patients on mono-therapy who still experience significant symptoms [134] , and could be routinely considered in patients with the EH phenotype. The addition of a second bronchodilator provides improvements in lung function, symptoms and exercise capacity compared with placebo or monotherapy, with little increase in side effects [115, 135, 136] .
The advent of new fixed-dose once-daily dual bronchodilator options such as indacaterol-glycopyrronium, vilanterol-umeclidinium, olodaterol-tiotropium and (twicedaily) formoterol-aclidinium bromide provide clinicians and patients with effective and simpler options for maximisation of bronchodilation. These combinations are at least as effective as the simultaneous use of their individual components (possibly via a synergistic effect [137, 138] ) and significantly improve lung function compared with monotherapy [139] [140] [141] [142] [143] [144] [145] . A positive effect on exercise tolerance has also been demonstrated for indacaterolglycopyrronium and vilanterol-umeclidinium compared with placebo [146, 147] , although the magnitude of this effect was less when compared to monotherapy with tiotropium.
Inhaled corticosteroids (ICS), on the other hand, have not consistently been associated with improvements in lung function and hyperinflation [148] . The combination of fluticasone and salmeterol was found to be superior to placebo in increasing exercise endurance time and decreasing hyperinflation, but was similar to salmeterol alone [149] . However, another study described the greater effect of combined budesonide-formoterol on exercise endurance time compared to formoterol alone. In addition, the addition of high-dose fluticasone to standard bronchodilator therapy resulted in a large clinically significant increase in endurance time and decrease in hyperinflation [150] .
The NETT trial [21] showed that, in patients with severe emphysema, LVRS conferred a 5-years survival advantage (risk ratio for death 0.86, p = 0.02) compared with optimal medical therapy [151] . The LVRS group also showed a decrease in exacerbation frequency [152] , improved exercise tolerance and quality of life through 3 and 4 years respectively. Patients with upper-lobe predominant emphysema and low exercise capacity were the ones in which LVRS was most beneficial, whereas those with very severe lung disease (FEV1 < 20 % predicted and either homogenous emphysema of DLCO < 20 % predicted) showed higher mortality rates in the perioperative period. Bronchoscopic lung volume reduction (BLVR) techniques such as endobronchial one-way valves and coils, instillation of biological agents and thermal vapour ablation are currently under investigation as promising nonsurgical approaches to emphysema treatment [153] .
Finally, comprehensive pulmonary rehabilitation (PR) remains a cornerstone of the management of patients with COPD [134, 154] and has a significant impact on dyspnoea, exercise tolerance, exacerbation rates, healthcare utilization and hyperinflation [154] [155] [156] . Improvements in exercise capacity are enhanced when PR is coupled with bronchodilator therapy [157] , emphasizing the importance of a multimodal approach to therapy.
Conclusion
The use of clinically relevant phenotypes in COPD allows for more coherent understanding of this heterogeneous disease. In this review, we highlighted the main characteristics of the EH phenotype in COPD: a heightened level of dyspnoea, marked exercise intolerance related to a critical constraint on lung volume expansion and hemodynamic consequences of hyperinflation, metabolic wasting and an adverse prognosis that is related to the degree of air trapping. As suggested by the Spanish GesEPOC guidelines, the management of patients with COPD can also be addressed in the light of the clinical phenotypes. In patients with EH, treatment should primarily focus on smoking cessation, the combination of maximal bronchodilation and pulmonary rehabilitation, while LVRS and BLVR techniques remain an option in highly selected patients. 
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